cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Iovance Biotherapeutics Inc
23 own
23 watching
Current Price
$11.72
$-0.08
(-0.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,326.18M
52-Week High
52-Week High
18.33000
52-Week Low
52-Week Low
3.21000
Average Volume
Average Volume
1.81M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,326.18M
icon52-Week High18.33000
icon52-Week Low3.21000
iconAverage Volume1.81M
iconDividend Yield--
iconP/E Ratio--
What does the Iovance Biotherapeutics Inc do?
Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.
Read More
How much money does Iovance Biotherapeutics Inc make?
News & Events about Iovance Biotherapeutics Inc.
Globe Newswire
10 months ago
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference: ...
Benzinga
1 year ago
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for lifileucel. read more...
Globe Newswire
1 year ago
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: H.C. Wainwright Cell ...
Ticker Report
1 year ago
Iovance Biotherapeutics (NASDAQ:IOVA Get Rating) had its price target hoisted by analysts at Truist Financial from $16.00 to $17.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the biotechnology companys stock. Truist Financial&#...
Globe Newswire
1 year ago
23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million The deal includes a 41.7 million milestone payment and double-digit Proleukin global sales royalties Clinigen Limited (Clinigen) (the Company), the global pharmaceutical services company, has entered into an ...
Frequently Asked Questions
Frequently Asked Questions
What is Iovance Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Iovance Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Iovance Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Iovance Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Iovance Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Iovance Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Iovance Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Iovance Biotherapeutics Inc?
plus_minus_icon
What percentage is Iovance Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Iovance Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$11.72
$-0.08
(-0.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$13.95
$0.25 (1.82 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$16.87
$-0.08 (-0.47 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.82
$-0.02 (-0.13 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$23.60
$-0.25 (-1.05 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$13.95
$0.25 (1.82 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$16.87
$-0.08 (-0.47 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.82
$-0.02 (-0.13 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$23.60
$-0.25 (-1.05 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00